Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT ON FORM 8-K - AETHLON MEDICAL INC | aethlon_8k-120910.htm |
Exhibit 99.1
JIM JOYCE
CHAIRMAN, CEO
LD MICRO CONFERENCE
December 9, 2010
MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD
LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING
WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND
INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER
PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND
OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW. SEC.GOV.
LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING
WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND
INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER
PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND
OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW. SEC.GOV.
Forward looking statements
Available Conference Documents
“A Platform Technology to Address
Bioterrorism”
Bioterrorism”
¤ 11/18/10
Shareholder Letter
¤ 12/1/10
California Equity Research Initiation
¤ 12/8/10
WE CREATE REVOLUTIONARY
DEVICES
DEVICES
THAT ADDRESS INFECTIOUS
DISEASE
DISEASE
& CANCER
THE FIRST MEDICAL DEVICE TO SELECTIVELY
FILTER VIRUSES AND IMMUNOSUPPRESSIVE
PARTICLES FROM CIRCULATION
FILTER VIRUSES AND IMMUNOSUPPRESSIVE
PARTICLES FROM CIRCULATION
THE HEMOPURIFIER®
Leveraging Established
Infrastructure
Infrastructure
Selectively Targets the
Removal of:
Removal of:
Subtractive
Therapy
Therapy
MEDICAL DEVICE VS.
BIOLOGIC REGULATORY
PATHWAY
BIOLOGIC REGULATORY
PATHWAY
70 TREATMENT EXPERIENCES IN
HUMANS
HUMANS
SUBSTANTIAL VIRAL LOAD
REDUCTION IN HIV AND HCV
INFECTED INDIVIDUALS
REDUCTION IN HIV AND HCV
INFECTED INDIVIDUALS
LEADING BROAD-
SPECTRUM
COUNTERMEASURE
AGAINST BIOTERROR &
PANDEMIC THREATS
SPECTRUM
COUNTERMEASURE
AGAINST BIOTERROR &
PANDEMIC THREATS
NEAR-TERM
COMMERCIALIZATION
PATHWAY OVERSEAS
COMMERCIALIZATION
PATHWAY OVERSEAS
IDE ON FILE WITH THE FDA
GMP MANUFACTURING
ESTABLISHED THROUGH
PARTNERSHIP WITH
NEXTPHARMA TECHNOLOGIES
ESTABLISHED THROUGH
PARTNERSHIP WITH
NEXTPHARMA TECHNOLOGIES
LOI SIGNED WITH MEMBRANA
FOR LARGE-SCALE
PRODUCTION
FOR LARGE-SCALE
PRODUCTION
HEMOPURIFIER® PROVIDES A
PIPELINE INTO THREE $ MULTI-
BILLION MARKETS
PIPELINE INTO THREE $ MULTI-
BILLION MARKETS
OUR WILDCARD MARKET
OPPORTUNITY
OPPORTUNITY
The Most Advanced Broad-Spectrum
Countermeasure
Countermeasure
Bioterror & Pandemic Threats
|
Virus
|
Collaborators
|
Human
Variety |
|
Ebola
|
CDC / USAMRIID
|
YES
|
|
Dengue
|
NIV / WHO
|
YES
|
|
Lassa
|
SFBR
|
YES
|
|
West Nile
|
Battelle
|
YES
|
|
H5N1 Avian
|
Battelle
|
YES
|
|
Spanish Flu of 1918-R
|
Battelle
|
YES
|
|
2009 H1N1 Swine
|
Battelle
|
YES
|
|
Monkey pox
|
Battelle
|
NO
|
“The Hemopurifier® is the only
strategy to address the breadth of
pathogens that could be weaponized
as agents of bioterror”
strategy to address the breadth of
pathogens that could be weaponized
as agents of bioterror”
Ken Alibek
OUR PRIMARY MARKET
FOCUS IS…..
FOCUS IS…..
TO ACCELERATE EARLY VIRAL LOAD
REDUCTION OF HCV STANDARD OF CARE
(SOC) DRUG THERAPY
REDUCTION OF HCV STANDARD OF CARE
(SOC) DRUG THERAPY
Hepatitis-C Virus (HCV)
IN THE ABSENCE OF DRUG
THERAPY
THERAPY
5 Day HCV Treatment Studies
ONE WEEK STUDY - THREE HEMOPURIFIER®
TREATMENTS
TREATMENTS
OUR STRATEGY IS TO
COMBINE OUR
HEMOPURIFIER® WITH HCV-
SOC TO ACCELERATE EARLY
VIRAL DEPLETION
COMBINE OUR
HEMOPURIFIER® WITH HCV-
SOC TO ACCELERATE EARLY
VIRAL DEPLETION
VIRAL FILTRATION HAS BEEN
PROVEN TO IMPROVE HCV
CURE RATES!
PROVEN TO IMPROVE HCV
CURE RATES!
Validation for Viral Filtration
Therapy
Therapy
Success
%
%
An Enduring Adjunct
Opportunity
Opportunity
¨ Hemopurifier® + Current SOC
¨ Hemopurifier® + Future Iterations of
SOC
SOC
¤ 65 drugs in competition
The Hemopurifier® + HCV SOC
Study
Study
¨ Enrollment has been initiated at the
Medicity
Medicity
¨ Up to 30 Patients
¨ Up to 6 treatments in first 3 days of SOC
¨ Clinical endpoints include:
¤ Immediate Virologic Response (IVR)
¤ Rapid Virologic Response (RVR)
¤ Early Virologic Response (EVR)
¨ Positive outcomes trigger
commercialization
commercialization
OUR HEMOPURIFIER® IS THE ONLY
TREATMENT STRATEGY TO ADDRESS DRUG
RESISTANT AIDS PATIENTS
TREATMENT STRATEGY TO ADDRESS DRUG
RESISTANT AIDS PATIENTS
Human Immunodeficiency Virus (HIV)
DO HIV INFECTED
INDIVIDUALS HAVE TO DIE
WHEN THEY NO LONGER
RESPOND TO THEIR MEDS?
INDIVIDUALS HAVE TO DIE
WHEN THEY NO LONGER
RESPOND TO THEIR MEDS?
IN THE ABSENCE OF DRUG
THERAPY
THERAPY
HIV/AIDS Patient Data
92% reduction of viral load
Improved CD4+ T-cell %
30 DAY STUDY - THREE HEMOPURIFIER® TREATMENTS PER WEEK
AIDS
IF YOU HAVE CANCER…………
EXOSOMES ARE SECRETED BY
ALL TUMORS, LYMPHOMAS, &
LEUKEMIAS
ALL TUMORS, LYMPHOMAS, &
LEUKEMIAS
Exosomes are
Immunosuppressive
Immunosuppressive
¨ Induce Apoptosis
¨ Disrupt T-Cell Signaling
¨ Inhibit Cytokine Production
¨ Angiogenesis
¨ Metastasis
Tumor-Secreted Exosomes
OUR HEMOPURIFIER® IS THE
SOLE THERAPEUTIC STRATEGY
TO ADDRESS
IMMUNSUPPRESSIVE EXOSOMES
SOLE THERAPEUTIC STRATEGY
TO ADDRESS
IMMUNSUPPRESSIVE EXOSOMES
GOAL IS TO MAXIMIZE THE
ABILITY OF THE IMMUNE
SYSTEM AND/OR OTHER
THERAPIES TO COMBAT
CANCER?
ABILITY OF THE IMMUNE
SYSTEM AND/OR OTHER
THERAPIES TO COMBAT
CANCER?
A Complementary Therapeutic
¨ Targets Benefit w/o
¤ Stacking additional drug
toxicity
toxicity
¤ Adding drug interaction risk
Recent Additions
to the AEMD
Team
to the AEMD
Team
September 3rd
FABIANI & COMPANY
ENGAGED
ENGAGED
TO REESTABLISH
BIODEFENSE & PANDEMIC
THREAT PROGRAMS
BIODEFENSE & PANDEMIC
THREAT PROGRAMS
October 26th
MIRIAM PROVOST NAMED
U.S. REGULATORY
ADVISOR
U.S. REGULATORY
ADVISOR
Miriam Provost
¨ 13 Years at FDA-ODE
¤ Deputy Director
¤ Division Director
¤ Branch Chief
October 28th
ROD KENLEY NAMED
PRESIDENT
PRESIDENT
Rod Kenley
¨ BAXTER
¤ Conceived the HomeChoice Peritoneal Dialyzer
n International Marketing Manager
n Director of Worldwide Product Planning
n Director of Advanced Product Development
¨ AKSYS LTD
¤ Founder
¤ Commercialized the PHD System, the first daily
home hemodialysis machine
home hemodialysis machine
¨ DEKA RESEARCH
The HomeChoice® Device
CREATE A PORTABLE
HEMOPURIFIER® TO DELIVER
IN-HOME BENEFIT
HEMOPURIFIER® TO DELIVER
IN-HOME BENEFIT
Selected 2011 Milestone
Targets
Targets
¨ HCV TREATMENT DATA
¨ HCV Commercialization
¨ Approval to Initiate U.S. Studies
¨ Clinical Partners Established in EU
¨ Multiple Bioterror Contract/Grant
Submissions
Submissions
¨ Cancer
¤ Data from multiple studies
¤ Disclosure of collaborative partnerships
¨ Advance Mobile/In Home Hemopurifier®
CREATING REVOLUTIONARY
DEVICES
DEVICES
THAT ADDRESS INFECTIOUS
DISEASE
DISEASE
& CANCER
JIM JOYCE
CHAIRMAN, CEO
8910 UNIVERSITY CENTER LANE
SAN DIEGO, CA. 92122
JJ@AETHLONMEDICAL.COM
858.459.7800 X301
ASSISTANT: CHARLENE OWEN
COWEN@AETHLONMEDICAL.COM
858.459.7800 X305
CHAIRMAN, CEO
8910 UNIVERSITY CENTER LANE
SAN DIEGO, CA. 92122
JJ@AETHLONMEDICAL.COM
858.459.7800 X301
ASSISTANT: CHARLENE OWEN
COWEN@AETHLONMEDICAL.COM
858.459.7800 X305